12m
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review
EyePoint Pharmaceuticals (EYPT) just shared that its pivotal Phase 3 trial for DURAVYU in wet age-related macular degeneration has passed the second independent safety committee review. This marks a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback